Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INCB 099280

Next Previous
Drug Profile

INCB 099280

Alternative Names: INCB-099280; INCB-99280

Latest Information Update: 30 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Incyte Corporation
  • Developer Incyte Corporation; Mirati Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours; Squamous cell cancer

Most Recent Events

  • 11 Jul 2025 Incyte Corporation terminates a phase I trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Italy, Spain, United Kingdom due to a strategic business decision. There were no safety concerns contributing to this decision (PO) (NCT06039384)
  • 06 Jun 2025 Incyte Corporation terminates a phase I/II trial in Solid tumours (Late-stage disease, Combination therapy, Second-line therapy or greater) in the United Kingdom due to a strategic business decision. There were no safety concerns contributing to this decision (PO) (NCT05949632)
  • 10 Jan 2025 Phase-I development in Solid tumours is ongoing in USA, Australia, Belgium, Japan, France (PO) (NCT04242199)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top